





















Cancer stem cells (CSCs) are tumor-initiating cells 
(TICs) [1, 2] that appear to be the biological basis of 
treatment failure, due to tumor recurrence and distant 
metastasis [3-7], ultimately leading to poor clinical 
outcome in cancer patients. As a consequence, new 
therapies are urgently needed, to specifically  target and  
 
eradicate CSCs [1-7]. Circulating tumor cells (CTCs) 
also directly share many key functional properties with 
CSCs [1-7]. 
 
Interestingly, recent studies indicate that one unique 
feature of CSCs is a characteristic increase in mito-
chondrial mass [8], which may reflect a more strict 
dependence on mitochondrial function or OXPHOS 
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Tri‐phenyl‐phosphonium  (TPP)  is  a  non‐toxic  chemical moiety  that  functionally  behaves  as  a  mitochondrial
targeting signal  (MTS)  in  living cells. Here, we explored  the hypothesis that TPP‐related compounds could be
utilized to inhibit mitochondria in cancer stem cells (CSCs). We randomly selected 9 TPP‐related compounds for
screening, using an ATP depletion assay. Based on this approach, five compounds were  identified as “positive
hits”;  two  had  no  detectable  effect  on  ATP  production.  Remarkably,  this  represents  a  >50%  hit  rate.  We
validated that the five positive hit compounds all inhibited oxygen consumption rates (OCR), using the Seahorse
XFe96 metabolic flux analyzer.  Interestingly, these TPP‐related compounds were non‐toxic and had little or no
effect on ATP production  in normal human  fibroblasts, but selectively  targeted adherent “bulk” cancer cells.
Finally,  these  positive  hit  compounds  also  inhibited  the  propagation  of  CSCs  in  suspension,  as  measured
functionally using the 3D mammosphere assay. Therefore, these TPP‐related compounds successfully inhibited
anchorage‐independent growth, which  is normally associated with a metastatic phenotype.  Interestingly, the
most  effective molecule  that we  identified  contained  two  TPP moieties  (i.e.,  bis‐TPP). More  specifically,  2‐
butene‐1,4‐bis‐TPP  potently  and  selectively  inhibited  CSC  propagation,  with  an  IC‐50  <  500  nM.  Thus,  we
conclude that the use of bis‐TPP, a “dimeric” mitochondrial targeting signal, may be a promising new approach
for the chemical eradication of CSCs. Future studies on the efficacy of 2‐butene‐1,4‐bis‐TPP and its derivatives
are  warranted.  In  summary,  we  show  that  TPP‐related  compounds  provide  a  novel  chemical  strategy  for
effectively  killing both  i)  “bulk”  cancer  cells and  ii) CSCs, while  specifically minimizing or avoiding off‐target
side‐effects  in  normal  cells.  These  results  provide  the  necessary  evidence  that  “normal”  mitochondria  and
“malignant”  mitochondria  are  truly  biochemically  distinct,  removing  a  significant  barrier  to  therapeutically
targeting cancer metabolism. 
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[9,10]. Several independent lines of evidence support 
the idea that increased mitochondrial biogenesis or 
higher levels of mitochondrial protein translation may 
occur in CSCs [8-18]. For example, unbiased pro-
teomics analysis directly shows that mitochondrial mass 
is elevated in CSCs [8].  
 
Moreover, MitoTracker (a fluorescent mitochondrial 
dye) can be used successfully as a marker to identify 
and purify CSCs [9,10].  Specifically, the “Mito-high” 
cell population showed the greatest capacity for 
increased i) anchorage-independent growth and ii) 
tumor-initiating ability in vivo [10].  
 
High telomerase activity also directly correlated with 
high mitochondrial mass and the ability of CSCs to 
undergo proliferative expansion [13]. Similarly, high 
mitochondrial mass in CSCs was also specifically 
associated with mitochondrial ROS production 
(hydrogen peroxide) [12] and could be targeted with 
either: i) mitochondrial anti-oxidants [19,20], ii) 
inhibitors of mitochondrial biogenesis (doxycycline) 
[11,13,14,18] or OXPHOS (atovaquone) [11,16,17], 
and even iii) inhibitors of cell proliferation (palbociclib, 
a CDK4/6 inhibitor) [13].  
 
The above findings immediately suggest a new 
approach for the eradication of CSCs, via the 
development of novel mitochondrial inhibitors. Here, 
we provide a new strategy for the identification of novel 
non-toxic mitochondrial inhibitors, using TPP-based 

























TPP serves as a chemical mitochondrial targeting 
signal [21].  Importantly, we directly showed that these 
TPP compounds are non-toxic in normal fibroblasts, 
but potently target CSC propagation, with an IC-50 as 
low as 500 nM. Using this approach, 2-butene-1,4-bis-





Selective targeting of cancer cell mitochondria with 
TPP compounds 
 
In order to identify new molecules that can be used to 
target mitochondria within CSCs, we devised a screening 
approach, by employing CellTiter-Glo to measure 
intracellular levels of ATP in adherent cancer cells 
(MCF-7).  As ~85% of cellular ATP is normally derived 
from mitochondrial metabolism, ATP levels are an 
excellent read-out to monitor mitochondrial function. In 
parallel, the same 96-well plates were also stained with 
Hoechst 33342, to measure DNA content, to allow us to 
gauge cell viability.  
 
Tri-phenyl-phosphonium (TPP) is a well-established 
chemical mitochondrial targeting signal. Cargo mo-
lecules covalently attached to TPP accumulate within 
the mitochondria of living cells. Therefore, we 
randomly selected 9 TPP derivatives and subjected 
them to screening in our assay system. The chemical 
structures of these TPP-derivatives are shown in 
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Notably, five out of the nine TPP compounds were 
“positive hits” that significantly reduced ATP levels. 
These positive hits included: 2-butene-1,4-bis-TPP, 2-
chlorobenzyl-TPP, 3-methylbenzyl-TPP, 2,4-dichloro-
benzyl-TPP and 1-naphthylmethyl-TPP. This represents 
a hit rate of >50%.  
 
However, two compounds were completely ineffective 
in reducing ATP levels (See Table 1). This finding is 














































moiety is not intrinsically toxic for normal cell 
mitochondria [21]. 
 
After initial screening, the five positive hit compounds 
were then subjected to further validation studies, shown 
in Figures 2-4, demonstrating that these TPP com-
pounds are highly active in the range of 0.5 to 2 μM.  
Based on this initial analysis, 2-butene-1,4-bis-TPP 
















































 Hoechst staining (%) ATP level (%) 
mito-TEMPO*  100.0 100.0  
cyanomethyl-TPP  97.2 95.1  
4-cyanobenzyl-TPP  72.7 68.2  
p-xylylene-bis-TPP  69.1 43.9  
*(2‐(2,2,6,6‐tetramethylpiperidin‐1‐oxyl‐4‐ylamino)‐2‐oxoethyl‐TPP.  Cell  viability  and  intra‐
cellular ATP  levels were determined  in  the  same  treated  samples. MCF‐7  cell  line, 50  μM 
treatment for 72 hours.  
Figure 2. Effect of TPP derivatives on cell viability and  intracellular ATP  levels  in MCF‐7 human
breast cancer cells: Compound 1. Cell viability and intracellular ATP levels were determined in the same
treated  samples. Hoechst  staining  (%)  (shown  in black bars); ATP  levels  (%)  indicated  in white bars. MCF‐7
cells were treated for 72h. Data are represented as mean +/‐ SEM. Note that 2‐butene‐1,4‐bis‐TPP depletes
ATP levels, relative to cell number. **p < 0.01; ***p < 0.001; indicates significance, all relative to the control. 











































Figure 5 highlights that these TPP compounds are 
relatively non-toxic in normal human fibroblasts 
(hTERT-BJ1), but are preferentially active in cancer 
cells (MCF-7). For example, in human fibroblasts, 2-
butene-1,4-bis-TPP had no effect on cell viability and 
only mildly reduced ATP levels by 25%. In contrast, at 
the same concentration (1 μM) in MCF-7 cancer cells, 
2-butene-1,4-bis-TPP reduced cell viability by nearly 
65% and decreased ATP levels by almost 85%. 
Therefore, 2-butene-1,4-bis-TPP was 2.8-fold more 
effective at reducing cell viability in cancer cells (versus 
fibroblasts). Similarly, 2-butene-1,4-bis-TPP was 4.7-
fold more effective at reducing ATP levels in cancer 











































were obtained with the other TPP compounds that we 
evaluated.   
 
Identifying TPP compounds that target “malignant” 
mitochondria in CSCs 
 
To further validate that the effects we observed on 
reducing ATP levels were indeed due to the inhibition 
of mitochondrial function, we directly measured 
mitochondrial oxygen consumption rates (OCR) using 
the Seahorse XFe96 metabolic flux analyser. The results 
are shown in Figures 6-8. All five compounds behaved 
similarly, and effectively reduced basal mitochondrial 
respiration, with an IC-50 of approximately 1 μM.  
Figure  3.  Effect  of  TPP  derivatives  on  cell  viability  and
intracellular ATP levels in MCF‐7 human breast cancer cells:




Note  that  both  2‐chlorobenzyl‐TPP  and  3‐methylbenzyl‐TPP
progressively deplete cellular ATP levels. *p < 0.05; **p < 0.01; ***p
< 0.001; indicates significance, all relative to the control. 
Figure  4.  Effect  of  TPP  derivatives  on  cell  viability  and
intracellular ATP levels in MCF‐7 human breast cancer cells:




Note  that  both  2,4‐dichlorobenzyl‐TPP  and  1‐naphtylmethyl‐TPP
progressively deplete cellular ATP levels. *p < 0.05; **p < 0.01; ***p
< 0.001; indicates significance, all relative to the control. 



















































































































BJ1) and human breast cancer cells (MCF‐7). Cell viability and  intracellular ATP  levels were determined  in the same
treated samples. Hoechst staining (%) of hTERT‐BJ1 human fibroblasts (black); ATP level (%) of hTERT‐BJ1 human fibroblasts
(dotted); Hoechst staining (%) of MCF‐7 cells  (inclined  lines); ATP  level (%) of of MCF‐7 cells (white). TPP treatments at 1
µM, 72h. Data are represented as mean +/‐ SEM. *p < 0.05; **p < 0.01; indicates significance, all relative to the control. 
Figure  6.  Impaired  mitochondrial  function  of  MCF‐7  cells  after  treatment  with  various  TPP
derivatives: Compound 1. Oxygen consumption rate (OCR) was measured with a Seahorse XF96 Extracellular
Flux  Analyzer.    Data  are  represented  as mean  +/‐  SEM.  Note  that  2‐butene‐1,4‐bis‐TPP  effectively  inhibits
mitochondrial oxygen consumption. **p < 0.01; ***p < 0.001; indicates significance, all relative to the control. 









































We next evaluated the effects of these TPP compounds 
on the propagation of CSCs, using the mammosphere 
assay as a read-out (Figure 9). Interestingly, 2-butene-
1,4-bis-TPP was the most effective, with an IC-50 < 
500 nM.  In contrast, for two of the other compounds 
tested (2-chlorobenzyl-TPP; 3-methylbenzyl-TPP) the 
IC-50 was between 1 to 5 μM. Finally, 1-naphthyl-
methyl-TPP was the least potent, with an IC-50 > 5 μM.  
Therefore, we conclude that 2-butene-1,4-bis-TPP is 2- 
to 10-fold more potent than the other TPP compounds, 
for inhibiting CSC propagation.  This is despite the fact 
that they all behaved nearly identically in reducing 
mitochondrial respiration and ATP production. 
Therefore, another intrinsic property of 2-butene-1,4-










































Finally, we used the xCELLigence system to visualize 
the kinetics of the effectiveness of 2-butene-1,4-bis-
TPP on the proliferation of adherent MCF-7 cells, for 
further validation. The xCELLigence system allows 
the real-time, label-free, monitoring of cell health and 
behavior, via high frequency measurement of cell-
induced electrical impedance.  Figure 10 shows that 
the effects of 2-butene-1,4-bis-TPP are concentration-
dependent and most notable after 72 hours, but are 
also noticeable at 48 hours. Interestingly, 2-butene-
1,4-bis-TPP was cytostatic at 1 μM. However, little or 
no effect was observed after 24 hours of incubation, 













Extracellular  Flux  Analyzer.  Data  are  represented  as mean  +/‐  SEM. 
Note  that  2,4‐dichlorobenzyl‐TPP  and  1‐naphtylmethyl‐TPP  both 
effectively  inhibit  mitochondrial  oxygen  consumption.  **p  <  0.01; 
***p < 0.001; indicates significance, all relative to the control. 
















































































































behavior, via high  frequency measurement of cell‐induced electrical  impedance. Note  that  the effects of 2‐butene‐
1,4‐bis‐TPP are concentration‐dependent and most notable after 72 hours, but are also noticeable at 48 hours. Little
or no effect was observed after 24 hours of incubation. Interestingly, 2‐butene‐1,4‐bis‐TPP was cytostatic at 1 μM.  
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DISCUSSION 
 
TPP is a mitochondrial targeting signal, which is non-
toxic in normal cells [21]. We hypothesized that TPP-
tagged molecules could be employed to inhibit 
mitochondrial function in CSCs (Figure 11).  To test 


















































to screen the activity of nine randomly selected TPP 
compounds. As a consequence, we found five TPP-
related compounds that significantly suppressed ATP 
levels, which yields a hit-rate of more than 50%. All 
five positive hit compounds were subjected to func-
tional validation with the Seahorse XFe96, to quantitate 


















































Figure  11. Overall Work‐Flow:  Identifying mitochondrial  inhibitors  to  target  CSC
propagation. Here, we selected TPP‐related compounds as the starting point for screening,




eradicating  cancer  stem  cells  (CSCs).  The  “dimeric”  structure  of
bis‐TPP is shown, where R represents any chemical group or moiety.  
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rate (OCR). Remarkably, these TPP hit compounds 
were non-toxic in normal human fibroblasts and did not 
affect their viability or ATP production, showing 
striking selectively for cancer cells. Most importantly, 
these TPP hit compounds successfully blocked CSC 
propagation, as shown by employing the 3D spheroid 
assay. For example, 2-butene-1,4-bis-TPP was the most 
potent molecule that we identified, which targeted CSC 
propagation with an IC-50 < 500 nM.  Interestingly, 2-
butene-1,4-bis-TPP contains two TPP groups. This 
suggests that the use of a bis-TPP moiety may function 
as a “dimeric” or “polymeric” signal for the more 
effective targeting of mitochondria in CSCs (Figure 12).  
However, further studies will be necessary to fully 




In summary, we conclude that TPP-related compounds 
may provide a novel chemical strategy for effectively 
targeting “bulk” cancer cells and CSCs, while mini-


































In this context, bis-TPP may represent a more potent 
and selective form of TPP, especially for targeting 
CSCs. However, part of this potency and selectivity 
may also come from the reactive double bond in the 
central butene moiety, as p-xylylene-bis-TPP (Table 1) 
was ~200 times less effective than 2-butene-1,4-bis-TPP 
(Figure 2), in reducing overall ATP levels. See Figure 
14 for a side-by-side structural comparison of these two 




























MATERIALS AND METHODS 
 
Cell culture and reagents 
 
The human breast adenocarcinoma cell line (MCF-7) 
was purchased from the American Type Culture 
Collection (ATCC). hTERT-BJ1 cells were originally 
purchased from Clontech, Inc. MCF-7 and hTERT-BJ1 
cells were grown in DMEM supplemented with 10% 
fetal bovine serum, GlutaMAX and 1% penicillin-
streptomycin and incubated at 37C in a humidified 5% 
CO2 incubator. The medium was changed 2-3 times/ 
week. Nine random TPP derivatives were purchased 
from Santa Cruz Biotechnology, Inc., as follows: (1) 2-
butene-1,4-bis-TPP; (2) 2-chlorobenzyl-TPP;  (3) 3-
methylbenzyl-TPP; (4) 2,4-dichlorobenzyl-TPP; (5) 1-
Figure  14.  bis‐TPP:  Structural  activity  relationships
(SARs). Comparison of 2‐butene‐1,4‐bis‐TPP (see Figures 1 and
2) with p‐xylylene‐bis‐TPP  (see Figure 1 and Table 1),  the  latter
of which is approximately 200‐fold less potent, in the context of
ATP depletion.  
Figure  13.  TPP‐related  compounds  provide  a  novel
chemical  strategy  for  targeting  “bulk”  cancer  cells  and
CSCs,  while  minimizing  off‐target  side‐effects  in  normal
cells.  Our  results  suggest  that  “malignant”  mitochondria  are
functionally  distinct  from  “normal”  mitochondria.  See  text  for
further details.  
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naphthylmethyl-TPP; (6) mito-TEMPO; (7) cyano-
methyl-TPP; (8) p-xylylene-bis-TPP; (9) 4-cyano-
benzyl-TPP. 
 
ATP-depletion assay (with CellTiter-Glo & Hoechst 
33342) 
 
MCF-7 cells were treated with different TPP derivatives 
for 72 hours in a black 96-well plate then wells were 
washed with PBS and were stained with Hoechst 33342 
dye at a final concentration of 10 μg/ml.  Fluorescence 
was read by a plate reader at 355 nm (excitation), 460 
nm (emission). After washing with PBS CellTiterGlo 
luminescent assay (Promega) was performed according 
to the manufacturer’s protocols to determine intra-
cellular ATP levels in the Hoechst dye stained cells. 
Both the fluorescent and luminescent data were 
normalized to control levels and were shown as 
percentage for comparison.  
 
Measuring the mitochondrial oxygen consumption 
rate (OCR) 
 
Mitochondrial function was determined by using the XF 
Cell Mito Stress Test Kit (Seahorse Bioscience, MA, 
USA) with a Seahorse XFe96 Extracellular Flux 
Analyzer (Seahorse Bioscience, MA, USA). MCF-7 
cells were seeded in a specialized 96-well tissue culture 
plate (XF96 microplate). Next day TPP derivatives were 
added and the plate was incubated for 72 hours. Before 
the experiment media was changed to XF base medium 
(including 1 mM pyruvate, 2 mM glutamine and 10 mM 
glucose) and cells were incubated at 37°C in a CO2-free 
atmosphere for one hour before measurement. After 
detection of basal oxygen consumption rate (OCR) (an 
indicator for mitochondrial respiration) OCR responses 
were evaluated towards the application of oligomycin (1 
µM), FCCP (600 nM), and the combination of anti-
mycin (1 µM) and rotenone (1 µM). From these 
measurements various parameters of mitochondrial 
function were determined. To determine cell viability in 
the measured wells sulphorodamine (SRB) assay was 
performed. Oxygen consumption rate (OCR) values 
were then normalized to the given SRB values.  
 
3D Spheroid (mammosphere) assay 
 
A single cell suspension of MCF-7 cells was prepared 
using enzymatic (1x Trypsin-EDTA, Sigma Aldrich, 
#T3924) and manual disaggregation (25 gauge needle). 
Cells were plated at a density of 500 cells/cm2 in 
mammosphere medium (DMEM-F12 media including 
B27/20 ng/ml and EGF/PenStrep) in non-adherent 
conditions, in culture dishes coated with (2-
hydroxyethylmethacrylate) (poly-HEMA, Sigma, 
#P3932). Different TPP derivatives were previously 
diluted in the mammosphere media before addition of 
cells. Plates were maintained in a humidified incubator 
at 37°C at an atmospheric pressure in 5% (v/v) carbon 
dioxide/air. After 5 days of culture, spheres >50 μm 
were counted using an eyepiece graticule and 
mammosphere numbers were normalized to control 
treatments (cells treated with vehicle only).  
 
xCELLigence RTCA System (ACEA Biosciences 
Inc.)  
 
Briefly, 25,000 MCF-7 cells were seeded in each well 
and used to assess the efficacy of 2-butene-1,4-bis-TPP, 
via RTCA (real-time cell analysis), via the measurement 
of cell-induced electrical impedance. This approach 
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